Sanofi, Regeneron hit final nail on the IL-6 repurposing coffin as Kevzara fails PhIII
Sanofi and Regeneron are putting their IL-6 program for Covid-19 to bed after a pivotal study delivered definitively negative results.
The partners noted that the trial met none of the endpoints, primary or key secondary, when Kevzara was compared to placebo added to usual hospital care. The incidence of adverse events leading to death was similar across all three arms — 400mg drug, 200mg and placebo — at 10%. Between 11% and 13% of the Kevzara cohorts had serious infections, versus 12% of the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
